Over the past several years, cell therapy has seen explosive growth in the number and variety of applications and disease targets under exploration for commercialization, a trend that is unlikely to slow. The diversity of manufacturing strategies and technology to support this growth has also evolved, albeit more slowly. Cell therapy manufacturers now face a wider range of decisions when it comes to implementing automated solutions in their process. Committing to the wrong manufacturing technology early in commercialization can mean expensive, risky delays with late process transfers and comparability studies.
Key steps in the cell therapy manufacturing process include cell collection, genetic modification, cell expansion, formulation and fill and finish, all of which can benefit from modular automation whereby an equipment performs one task as part of a series and can integrate easily into an established or growing manufacturing process as a result of its simplicity and flexibility.
In this webinar we will introduce Terumo BCT’s new cell expansion platform: Quantum Flex. Building on the success and performance of hollow-fiber perfusion technology, Quantum Flex provides an optimized cell culture environment for adherent and suspension cell expansion, where cells thrive. Quantum Flex also features advanced software to support cGMP compliance, with user authentication, batch records and fleet management capabilities. This platform has the flexibility to process autologous and allogenic applications, as well as viral vector and exosome production, across multiple volumes of bioreactor, and showcases the scalability and connectivity to grow with your therapy, from process development to clinical manufacturing.